Sector News

Bayer cuts loose diabetes care division for 1.02bn euros

June 10, 2015
Life sciences
Bayer is shedding its diabetes care division via a deal with long-term partner Panasonic Healthcare Holdings worth 1.02 billion euros.
 
The sale includes blood glucose monitoring systems, including the popular Contour portfolio of testers and strips, as well as lancing devices for patients with diabetes, which helped the unit bring in sales of 909 million euros last year.
 
The move seems a good fit for Panasonic. “For more than 20 years, our companies have shared complementary goals. We anticipate that this partnership will take our two great businesses to new heights,” said Kenji Yamane, President of Panasonic Healthcare Holdings, which is owned by investment group KKR (80%) and Panasonic Corp (20%). 
 
For Bayer, the transaction comes under its current strategy of honing its focus on life-sciences, as per which it also plans to de-merge and float on the stock market its MaterialScience unit by mid-2016.
 
The deal with Panasonic, which remains subject to customary conditions, including relevant antitrust clearance, is expected to close in the first quarter of next year.
 
By Selina McKee
 

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach